Q3 2024 EPS Estimates for DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Cut by Barrington Research

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Barrington Research decreased their Q3 2024 earnings estimates for shares of DENTSPLY SIRONA in a report issued on Thursday, August 1st. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will post earnings per share of $0.47 for the quarter, down from their previous estimate of $0.53. Barrington Research has a “Outperform” rating and a $38.00 price objective on the stock. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.98 per share. Barrington Research also issued estimates for DENTSPLY SIRONA’s Q4 2024 earnings at $0.60 EPS, FY2024 earnings at $1.98 EPS, Q1 2025 earnings at $0.51 EPS, Q2 2025 earnings at $0.55 EPS, Q3 2025 earnings at $0.56 EPS, Q4 2025 earnings at $0.64 EPS, FY2025 earnings at $2.25 EPS and FY2026 earnings at $2.55 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Wednesday, July 31st. The medical instruments supplier reported $0.49 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.01). The firm had revenue of $984.00 million for the quarter, compared to the consensus estimate of $993.61 million. DENTSPLY SIRONA had a positive return on equity of 11.86% and a negative net margin of 4.75%. DENTSPLY SIRONA’s revenue for the quarter was down 4.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.51 EPS.

A number of other equities research analysts also recently weighed in on XRAY. The Goldman Sachs Group cut their price target on shares of DENTSPLY SIRONA from $34.00 to $30.00 and set a “neutral” rating for the company in a report on Monday, May 6th. Needham & Company LLC cut their target price on shares of DENTSPLY SIRONA from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Evercore ISI decreased their price target on shares of DENTSPLY SIRONA from $28.00 to $27.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 9th. Robert W. Baird cut their price objective on DENTSPLY SIRONA from $33.00 to $31.00 and set a “neutral” rating for the company in a research report on Monday, July 22nd. Finally, StockNews.com cut DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, DENTSPLY SIRONA has a consensus rating of “Moderate Buy” and a consensus target price of $33.44.

DENTSPLY SIRONA Trading Down 1.3 %

Shares of DENTSPLY SIRONA stock opened at $24.15 on Monday. The business has a fifty day simple moving average of $26.05 and a 200-day simple moving average of $29.84. The firm has a market cap of $5.01 billion, a price-to-earnings ratio of -54.89, a price-to-earnings-growth ratio of 1.23 and a beta of 1.01. DENTSPLY SIRONA has a fifty-two week low of $23.94 and a fifty-two week high of $39.81. The company has a quick ratio of 0.97, a current ratio of 1.33 and a debt-to-equity ratio of 0.57.

DENTSPLY SIRONA Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 11th. Shareholders of record on Friday, September 27th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $0.64 annualized dividend and a yield of 2.65%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is presently -145.45%.

Insider Activity

In related news, Director Gregory T. Lucier acquired 3,577 shares of the stock in a transaction that occurred on Friday, May 31st. The shares were purchased at an average cost of $27.95 per share, with a total value of $99,977.15. Following the completion of the transaction, the director now owns 58,374 shares of the company’s stock, valued at approximately $1,631,553.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.52% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Principal Securities Inc. purchased a new stake in shares of DENTSPLY SIRONA during the fourth quarter worth $26,000. Headlands Technologies LLC acquired a new position in DENTSPLY SIRONA in the 4th quarter worth about $30,000. Parkside Financial Bank & Trust raised its stake in shares of DENTSPLY SIRONA by 33.3% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,169 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 292 shares in the last quarter. VisionPoint Advisory Group LLC lifted its holdings in shares of DENTSPLY SIRONA by 57.1% during the 4th quarter. VisionPoint Advisory Group LLC now owns 1,216 shares of the medical instruments supplier’s stock valued at $43,000 after buying an additional 442 shares during the last quarter. Finally, LRI Investments LLC grew its stake in shares of DENTSPLY SIRONA by 82.7% in the 2nd quarter. LRI Investments LLC now owns 1,246 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 564 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.